Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Cellcyte Genetics Corp CCYG

"CellCyte Genetics Corp is a biotechnology development stage company. It is involved in research and development of medical devices for cell expansion and maintenance. Geographically the research activities are functioned through the region of United States."

GREY:CCYG - Post Discussion

Cellcyte Genetics Corp > SEC formal Investigation
View:
Post by halcrow on May 17, 2008 11:10am

SEC formal Investigation

David Baines, Vancouver Sun

Published: Saturday, May 17, 2008

The SEC has finally caught up to CellCyte Genetics Corp., another trashy Vancouver-inspired company that trades on the bulletin board.

In a filing this week, the company revealed that SEC enforcement staff commenced an informal inquiry in January, and upgraded it to a formal investigation in May.

As noted in previous columns, Cellcyte, based in Bothell, Wash., has been promoted by West Vancouver promoter Brent Pierce, who is currently under suspension from the B.C. market for serious securities violations.

Pierce paid nearly half a million dollars to U.S. newsletter writer James Rapholz to prepare and distribute a newsletter that made outrageous forecasts for CellCyte's share price. The Seattle Times also reported that CellCyte CEO Gary Reys had repeatedly fibbed on his curriculum vitae.

The stock soared to $7.42 in January this year, giving it a total stock market value of $450 million, but it has since collapsed to 46 cents. Shareholders have also filed three class action lawsuits alleging Cellcyte's officers and directors filed misleading statements with the SEC and on its website.

- - -

https://www.canada.com/vancouversun/news/business/story.html?id=8a1630a3-21b6-48e8-8b3e-2fdb6c92c92d

Be the first to comment on this post